Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer

被引：59

作者：

Farhat, Fadi S. ^{[2
]}

Tfayli, Arafat ^{[3
]}

Fakhruddin, Najla ^{[5
]}

Mahfouz, Rami ^{[4
]}

Otrock, Zaher K. ^{[3
]}

Alameddine, Raafat S. ^{[3
,6
]}

Awada, Ahmad H. ^{[1
]}

Shamseddine, Ali ^{[3
,7
]}

机构：

[1] Univ Libre Bruxelles, Inst Jules Bordet, Med Oncol Clin, B-1000 Brussels, Belgium

[2] Hammoud Hosp Univ Med Ctr, Dept Hematol Oncol, Saida, Lebanon

[3] Amer Univ Beirut, Med Ctr, Dept Internal Med, Beirut, Lebanon

[4] Amer Univ Beirut, Med Ctr, Dept Pathol & Lab Med, Fac Med, Beirut, Lebanon

[5] Hammoud Hosp Univ Med Ctr, Dept Pathol, Saida, Lebanon

[6] Amer Univ Beirut, Nayef K Basil Canc Ctr, Beirut, Lebanon

[7] Amer Univ Beirut, Div Hematol Oncol, Beirut, Lebanon

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2012年 / 84卷 / 02期

关键词：

Non-small cell lung cancer; VEGF; bFGF; Angiogenic markers; Expression; Prognostic impact; Review; ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; FACTOR MESSENGER-RNA; RANDOMIZED PHASE-II; INCREASED SERUM-LEVELS; TUMOR ANGIOGENESIS; FACTOR-C; CLINICAL-SIGNIFICANCE; LYMPHATIC VESSELS; FACTOR FAMILY;

D O I：

10.1016/j.critrevonc.2012.02.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite major advances in cancer therapeutics, the prognosis for lung cancer patients is still poor and the median survival for patients presenting with advanced non-small cell lung cancer (NSCLC) is only 8-10 months. Angiogenesis is an important biological process and a relatively early event during lung cancer pathogenesis. Anti-angiogenic agents are used in treating patients with NSCLC, and their molecular biomarkers are also being assessed to predict response. A better understanding of the biology of angiogenesis in NSCLC may reveal new targets for treating this malignancy. In this article, we review the expression and prognostic impact of the angiogenic growth factors, vascular endothelial growth factor and basic fibroblast growth factor, in NSCLC. (C) 2012 Published by Elsevier Ireland Ltd.

引用

页码：149 / 160

页数：12

共 119 条

[31] Clinical implication of expression of vascular endothelial growth factor-C in metastatic lymph nodes of uterine cervical cancers
Fujimoto, J
Toyoki, H
Sato, E
Sakaguchi, H
Tamaya, T
[J]. BRITISH JOURNAL OF CANCER, 2004, 91 (03) : 466 - 469
[32] INCREASED SERUM LEVELS OF BASIC FIBROBLAST GROWTH-FACTOR IN PATIENTS WITH RENAL-CELL CARCINOMA
FUJIMOTO, K
ICHIMORI, Y
KAKIZOE, T
OKAJIMA, E
SAKAMOTO, H
SUGIMURA, T
TERADA, M
[J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 180 (01) : 386 - 392
[33] THE HUMAN BASIC FIBROBLAST GROWTH-FACTOR GENE (FGFB) IS ASSIGNED TO CHROMOSOME-4Q25
FUKUSHIMA, Y
BYERS, MG
FIDDES, JC
SHOWS, TB
[J]. CYTOGENETICS AND CELL GENETICS, 1990, 54 (3-4): : 159 - 160
[34] Giatromanolaki A, 1998, CLIN CANCER RES, V4, P3017
[35] The BATTLE to Personalize Lung Cancer Prevention through Reverse Migration
Gold, Kathryn A.
Kim, Edward S.
Lee, J. Jack
Wistuba, Ignacio I.
Farhangfar, Carol J.
Hong, Waun Ki
[J]. CANCER PREVENTION RESEARCH, 2011, 4 (07) : 962 - 972
[36] GOTO F, 1993, LAB INVEST, V69, P508
[37] Gualandris A, 1996, CELL GROWTH DIFFER, V7, P147
[38] VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) EXPRESSION AND ANGIOGENESIS IN CERVICAL NEOPLASIA
GUIDI, AJ
ABUJAWDEH, G
BERSE, B
JACKMAN, RW
TOGNAZZI, K
DVORAK, HF
BROWN, LF
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (16) : 1237 - 1245
[39] Han H, 2001, ANN SURG ONCOL, V8, P72, DOI 10.1245/aso.2001.8.1.72
[40] Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D
Folkman, J
[J]. CELL, 1996, 86 (03) : 353 - 364

← 1 2 3 4 5 6 7 8 9 10 →